Clinical Trials

Inclusion Criteria:

• High to moderate clinically suspected IPMN following the consensus guidelines criteria: presence of a dilated main pancreatic duct ([MPD] ≥ 5 mm) or a cystically dilated branch duct (≥5 mm) or Individuals with a pancreatic cyst (either newly or previously diagnosed, or previously operated upon).
• Cyst surveillance is warranted, according to the treating physician.
• Age ≥ 18 years old.
• Informed consent.
• High resolution imaging technique (MRI, CT scan, or endoscopic ultrasonography [EUS]) performed as a baseline examination.

Exclusion Criteria:

• Patients who do not meet the above inclusion criteria.
• History of chronic pancreatitis.
• Suspected pseudocyst (simple, thin walled cyst that developed in the course of acute (necrotising) pancreatitis, as documented by sequential imaging studies).
• Suspected serous cystadenoma (typical microcystic lesion with lobulated outlines and a calcified central scar, and cyst fluid CEA levels < 5 ng/ml).
• Von Hippel-Lindau disease.
• Limited life expectancy (< 2 years).